Mobile technology facilitates virtual skin and wound testing
Dermatology care and clinical research often requires capturing images related to a patient’s condition, but with COVID-19 and other factors making travel to and from a medical facility a problem, a remote solution patient-centeredness might help. Carlos Perez, CEO and Co-Founder of Swift Medical, describes its artificial intelligence (AI)-powered platform and how the company’s technology is helping improve image capture and management in dermatology trials.
OSP: Could you please share an overview of Swift Medical – who you are, what you do, key specialties and what sets you apart.
CP: Swift Medical is the world leader in digital skin and wound management technology. Our AI-powered digital platform enables patients and clinicians to easily capture, track and analyze high-precision images of skin or wound condition with any smartphone camera .
Swift Medical’s technology is used by more than 4,000 healthcare organizations worldwide, including healthcare systems and providers across the continuum, academic institutions, research organizations and pharmaceutical companies. Swift Medical is the only wound management solution with clinically validated reliability and accuracy.
OSP: Could you please describe Swift Skin and Wound, how it works and what advantages does this technology offer over more conventional solutions?
CP: Swift Skin and Wound makes capturing accurate wound care information as easy as taking a photo and can be deployed to iOS or Android devices without using any external hardware. Swift offers significant benefits in wound management.
Color, size and shape calibration is supported by HealX, Swift’s proprietary cue marker. HealX is the only FDA registered reference marker available on the market. HealX ensures that image capture is standardized regardless of the image taker, environment or lighting.
Swift Skin and Wound autonomously determines clinical features, tracks disease progression, enables remote communication, and securely shares real-time patient data. Peer-reviewed studies have shown both significant improvements in the accuracy of wound measurement, as well as significant reductions in time compared to traditional methods of using a paper ruler for wound assessment. .
OSP: So please tell us how skin and wounds could be used in trials, especially decentralized studies. Does it require a home nurse or other trained professionals or is the patient able to self-scan?
CP: While Swift Skin and Wound was designed to support wound healing, Swift Scientific is our new platform specifically designed to support decentralized clinical trials for any type of dermatological or skin-related study. The COVID-19 pandemic has severely hampered clinical trials, making the recruitment, tracking and retention of participants more difficult and resulting in more expensive, delayed and sometimes canceled clinical trials.
Swift Scientific is able to support clinical trials at multiple sites, whether at the clinic or at the participant’s home, with a mobile app that eliminates the need for expensive equipment or extended travel. Taking measurements is simple and intuitive and can be performed by a clinician or a patient according to study protocols.
Swift Scientific was designed so that patients or caregivers without medical training can easily capture images for skin assessments; just open the app, point and shoot. Researchers are then able to analyze images and data in real time, from any remote location.
One of the main advantages of Swift Scientific is the support services we provide. We work alongside study sponsors and CROs to design the technological configuration of a given study protocol and have a dedicated team to support asynchronous and multi-site studies.
We can also work with partners to help create training material for participants that goes through IRB approval as well as all training material for sites, trial managers and instructors to ensure that our technology is being used to its full potential. Another benefit of using Swift Scientific is that all data is available for regular export to all required repositories, including all relevant metadata.
OSP: Do you have any partnerships with CROs or other medical organizations that you could tell us about?
CP: To date, Swift Scientific has been adopted at over 50 sites in North America and Europe with some of the largest pharmaceutical organizations in the world.
OSP: What’s the next step for your business? Do you have an exciting new technology on the horizon or another announcement that you would like to share?
CP: We have some very exciting announcements in the coming months, some of which will directly expand and improve the capabilities of Swift Scientific. Stay tuned!